Key Takeaways
- Margin recovery underway, revenue growth modest: Q4 EBITDA margin improved 141 bps YoY to 12.7%, while full-year revenue grew to INR2,079 crores. Management guided to >15% EBITDA margin and 10–15% revenue growth for FY26, betting on volume traction and price stabilization.
- Ibuprofen volumes improving despite price headwinds: The backward-integrated facility sustains ~85–90% capacity utilization and cost leadership, and the new China CDE approval opens a material new market, though management declined to quantify pricing or margin differentials until customer dispatches begin.
- Non-Ibuprofen diversification is working: The non-Ibu portfolio has grown from 18% to ~34% of API revenues over five years, with Clopidogrel, Fenofibrate, Pantoprazole and Levetiracetam driving stable demand and regulatory progress across Europe, U.S. and Brazil.
- Chemical segment is stabilizing, not yet contributing: Ethyl acetate prices have bottomed out and chemical EBITDA margin rose to 6% in Q4 from 3% a year ago, but the segment remains an enabler of cost efficiency rather than an independent growth engine.
- What to watch next quarter: Whether the promised 10–15% revenue growth materializes, the pace of Ibuprofen customer conversion in China, and any movement on the U.S. FDA inspection timeline, which management cannot yet forecast.
Margin & Profitability
- Q4 margin walk: EBITDA margin improved 141 bps YoY to 12.7%, driven by lower power and fuel costs after switching to rice as fuel, plus scale efficiency in chemicals. Full-year EBITDA margin was ~11%.
- PAT hit by depreciation, not operations: Reported PAT was depressed by higher depreciation from recent capital investments. Cash PAT was INR56.4 crores in Q4 and INR185 crores for FY25, showing strong underlying cash generation.
- Other expenses structurally lower: Other expenses fell from INR81 crores to INR65–70 crores, mainly because power and fuel costs dropped drastically in FY25. Management expects this INR65–70 crores range to sustain.
- Chemical margin trajectory: Chemical EBITDA margin rose to 6% in Q4 FY25 from 3% in Q4 FY24, driven by maximum production quantity of ethyl acetate and acetic anhydride. The target is ~10%, with management expecting to exceed 6% in FY26.
- Pharma EBIT declined on price, not volume: Pharma EBIT fell from INR174 crores to INR126 crores in FY25. Management believes API prices have been at bottom for 2–3 quarters and quantity production is now increasing.
- Ibuprofen margins lead, but non-Ibu has catch-up potential: Ibuprofen margins are currently higher than all non-Ibu products, but non-Ibu products have potential for equivalent or higher EBITDA margins once regulatory-market revenue scales.
Kushal Kumar Rana: "In the fourth quarter of '25, we have achieved 6% EBITDA margin from chemicals as compared to '24, 3%. So we are going forward to 10%. So hopefully in the current year, we will achieve more than 6%."
Ibuprofen: Volume, Cost & China Entry
- Cost leadership anchored in backward integration: The facility is backward integrated and commands the full chain, making IOL one of the most cost-efficient Ibuprofen producers globally. Capacity utilization is sustaining at ~85–90%.
- China CDE approval opens a new demand pool: The approval is an important milestone for expanding global reach. Management has started touching customers and expects good volumes for Ibuprofen and derivatives, but will only forecast numbers after customer realization and dispatches begin.
- Pricing and margin differentials undisclosed: Management declined to comment on China pricing versus Europe or domestic markets, saying it is too early. On margins, the general view is they are "almost same" across markets, but this depends on requirement and varies order-to-order.
- Competitive landscape manageable for now: Management sees no big problem from new Ibuprofen players currently, calling it an open market they will deal with when competitors arrive. When asked about competitor losses, management deflected, saying they cannot comment on how others are doing.
Abhay Raj Singh: "we are the backward integrated facility and we command the backward chain also and we are considered as one of the best cost-efficient company for the Ibuprofen"
Non-Ibuprofen Diversification
- Portfolio transformation in five years: Non-Ibuprofen APIs have grown from 18% to ~34% of API revenues, spanning antidiabetics, analgesics, anticholesterol, antiepileptic and cardiovascular categories. Products like Metformin, Paracetamol, Fenofibrate, Pantoprazole, Levetiracetam and Clopidogrel are seeing stable demand.
- Clopidogrel capacity expanded 33% to meet demand, and volumes exceeded plan in FY25 alongside Pantoprazole and Fenofibrate. Pricing for these products is stable and not declining, with improvement expected.
- Levetiracetam regulatory build-out: Capacity enhancements are done, a U.S. DMF has been filed, a CEP obtained, and ANVISA approval secured for Brazil. Management expects good volumes in the near future, targeting Europe first, then the U.S. and India in parallel, then Brazil.
- Fenofibrate U.S. entry: A U.S. DMF approval was received, and a customer obtained ANDA approval after 2–3 questions on the DMF, opening the U.S. market.
- Metformin U.S. access via customer ANDA: Metformin is U.S. FDA approved through a customer's ANDA, allowing IOL to sell to that customer who manufactures drugs in India for the U.S. market.
- New CEP approvals for Mesalazine and Quetiapine: Planning to run these in a multiproduct facility to start feeding the market, with a commercial facility to follow.
- Paracetamol demand lagged: Demand was not up to mark during FY25 and remains at bottom-level pricing with no significant improvement yet. Management expects some improvement given the current geographical scenario. Old 3,600 MTPA plant production will shift to the new 10,800 MTPA plant, with eventual capacity at 10,800 tons.
Rakesh Mahajan: "No doubt our ibuprofen margins are presently more than all other non-Ibu segment. But all other non-Ibu segment products are also potential to have EBITDA margin equivalent or more than Ibuprofen also, but it may take some time or it may take more revenue from the regulatory market, which we are trying for exploring that market at the earliest."
Chemical Segment: Stabilization, Not Growth
- Ethyl acetate prices bottomed out: Prices were very fluctuating about a year back but have been stable for the last 2–3 quarters, along with stable raw material prices. Demand is showing some traction and may increase in 1–2 quarters.
- Volume increased in Q4, and the segment achieved maximum production quantity of both ethyl acetate and acetic anhydride, driving scale efficiency.
- Export recertification unlocked chemical exports: Chemical export revenue share rose from 10–12% to ~18% in FY25 after receiving recertification for ethyl acetate. Acetic anhydride recertification from Europe is under process and expected very soon.
- Strategic role is cost enabler, not growth engine: Management frames the chemical business as an enabler of cost efficiency and supply reliability, not an independent growth engine exposed to global demand cycles.
Abhay Raj Singh: "our chemical business is an enabler of cost efficiency and supply reliability not an independent growth engine exposed to global demand cycle"
Capex, Capacity & Greenfield Expansion
- Greenfield land acquired: 101 acres along the Chandigarh-Bathinda Highway for greenfield expansion. Approvals for industrial, environmental and National Highway clearances are underway and progressing into FY26.
- FY26 capex plan: INR150–200 crores planned, including growth capex, infrastructure, automation and developments.
- Peak revenue from existing capacity: At current prices, existing capacity can generate INR2,700–2,800 crores.
- Backward integration R&D underway: The R&D team is working on backward integration for existing products, with disclosures promised at the appropriate time.
- DCDA manufacturing ruled out: No plans to manufacture DCDA because the basic input material has demand-supply issues.
Export Trajectory & Regulatory Milestones
- Export share dipped on price, not volume: Export share fell from 29–30% in 2023 to 27% due to underutilization of the European market from the Ukraine war impact and lower API prices in FY25 versus FY23. Volume actually increased.
- Ambitious export target: Management aims to scale export revenues to 40–45% over the medium term, hoping to achieve this in the next 2 years.
- U.S. FDA inspection timing unknown: Management has no information on when a U.S. FDA inspection will take place, though the company states it is ready.
- Three patents approved: Management confirmed three approved patents. When asked about an Edoxaban patent filing, the response was non-committal: "I also check and then come back to you if required if there is any change."
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Revenue growth | 10–15% from all products, mix of volume and price | FY26 |
| EBITDA margin | More than 15% | FY26 |
| Chemical EBITDA margin | More than 6%, targeting ~10% | FY26 |
| Export revenue share | Scale to 40–45% | Next 2 years |
| Peak revenue from existing capacity | INR2,700–2,800 crores at current prices | No date |
| Capex | INR150–200 crores including growth, infra, automation | FY26 |
| Paracetamol capacity consolidation | Shift old 3,600 MTPA to new 10,800 MTPA plant; eventual capacity 10,800 tons | No date |
| Acetic anhydride Europe recertification | Under process, expected very soon | No date |
| Greenfield expansion | Environmental clearance and NHI/Pollution Control Board permissions started | Progressing into FY26 |
Key Metrics
| Metric | Q4 FY25 |
|---|---|
| Revenue from operations | ₹528 cr, 4.7% YoY growth vs ~₹504 cr in Q4 FY24 |
| Full-year FY25 revenue | ₹2,079 cr |
| EBITDA | ~₹67 cr, up 17% YoY from ~₹58 cr in Q4 FY24 |
| EBITDA margin | 12.7%, improvement of 141 bps YoY |
| Full-year FY25 EBITDA margin | ~11% |
| PAT | ₹31.6 cr, up 12% YoY from ₹28 cr in Q4 FY24 |
| PAT margin | 5.9%, increase of 43 bps YoY |
| Full-year FY25 PAT | ₹101 cr, PAT margin 4.8% |
| Cash PAT | ₹56.4 cr, up ~15% YoY from ₹49.2 cr in Q4 FY24 |
| Full-year FY25 cash PAT | ₹185 cr |
| Net debt to equity ratio | 0.09 at end of FY25 |
| Revenue split (Ibuprofen vs non-Ibuprofen) | ~65% Ibuprofen, ~35% non-Ibuprofen |
| Non-Ibu portfolio share of API revenues | ~34%, up from 18% five years ago |
| Chemical segment EBITDA margin | 6%, vs 3% in Q4 FY24 |
| Export revenue share | 27%, target 40%–45% over medium term |
| Chemical export revenue share | ~18% during FY25, up from 10%–12% previously |
| Peak revenue from existing capacity | ₹2,700–2,800 cr at current prices |
| Expected FY26 revenue growth | 10% to 15%, mix of volume and price |
| Expected FY26 EBITDA margin | more than 15% |
| FY26 capex plan | ₹150–200 cr, same as last 2–3 years |
| Paracetamol capacity (new plant) | 10,800 MTPA, old plant of 3,600 MTPA to be phased out |
| Clopidogrel capacity expansion | 33% increase |
| DMFs filed | 16 |
| CEPs filed | 19 |
| Land acquired for greenfield expansion | 101 acres along Chandigarh-Bathinda Highway |